Malaria is common in areas such as Africa, South America, and Southern Asia. This medicine is not effective against all strains of malaria. Is gastrointestinal problems common from plaquenil Hydroxychloroquine tablets Jan 31, 2019 Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib together with hydroxychloroquine may work better in treating patients with pancreatic cancer. FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA Preliminary Results From a Phase I/II Clinical Treatment Trial. This phase I / II trial studies the side effects and best dose of hydroxychloroquine when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IV melanoma that has spread to other places in the body. Taking hydroxychloroquine long-term or at high doses may cause irreversible damage to the retina of your eye. Hydroxychloroquine is also an antirheumatic medicine and is used to treat symptoms of rheumatoid arthritis and discoid or systemic lupus erythematosus. Trametinib hydroxychloroquine PLAQUENIL HYDROXYCHLOROQUINE SULFATE TABLETS, USP DESCRIPTION, FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK. Is hydroxychloroquine hepatoticSymptoms of plaquenil eye toxicityPlaquenil and celiacHydroxychloroquine side effectsPlaquenil drug card A Phase I clinical trial to study the side effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer. Phase I Study of Trametinib and Hydroxychloroquine in Treating Patients.. Dabrafenib, Trametinib and Hydroxychloroquine in Treating Patients with.. Dabrafenib, Trametinib and Hydroxychloroquine in Treating.. Correction The text describing a single-arm skin cancer study evaluating trametinib plus Novartis’s BRAF inhibitor dabrafenib with the addition of hydroxychloroquine for patients. Hydroxychloroquine is a 4-aminoquinoline in use for more than 30 years for the treatment of malaria, rheumatoid arthritis, and systemic lupus erythematosus. A recent study shows that the combination of MEK inhibitor trametinib and hydroxychloroquine led to a striking disease response in a patient with pancreatic cancer. Hydroxychloroquine is a quinoline medicine used to treat or prevent malaria, a disease caused by parasites that enter the body through the bite of a mosquito. Malaria is common in areas such as Africa, South America, and Southern Asia. This medicine is not effective against all strains of malaria.